Nanobiotix (LTS:0QAV) Other Financing: €-0.77 Mil (TTM As of Dec. 2025)


LTS:0QAV Nanobiotix SA LTS:0QAV
28 GF Score
Price €34.88
! 3 Warning Signs
View Full Analysis

What is Nanobiotix Other Financing?

Nanobiotix LTS:0QAV +3.91% 28 Other Financing is €-0.77 Mil as of Dec. 2025. GuruFocus rates LTS:0QAV with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Nanobiotix's Other Financing for the six months ended in Dec. 2025 was €-0.44 Mil.

Nanobiotix's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.77 Mil.

Nanobiotix Other Financing Historical Data

* Premium members only.

The historical data trend for Nanobiotix's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix Other Financing Chart

Nanobiotix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -0.92 -9.77 -0.98 -2.31

Nanobiotix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.79 -0.61 -0.37 -0.34 -0.44
LTS:0QAV
28GF Score
Nanobiotix SA LTS:0QAV
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanobiotix Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.77 Mil mean?
Nanobiotix (LTS:0QAV) has a Other Financing of €-0.77 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nanobiotix and its competitors.
Is Nanobiotix's Other Financing too high?
Nanobiotix's current Other Financing is €-0.77 Mil. Overall, Nanobiotix has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's Other Financing compare to VRTX and REGN?
Nanobiotix's Other Financing of €-0.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nanobiotix and its competitors. Nanobiotix's current Other Financing is €-0.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (LTS:0QAV) has a current Other Financing of €-0.77 Mil. The current Other Financing is €-0.77 Mil. Nanobiotix's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Nanobiotix (LTS:0QAV), the current Other Financing is €-0.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanobiotix Business Description

Address 60 Rue de Wattignies, Paris, FRA, 75012
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
28GF Score

Get the complete analysis for LTS:0QAV

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.88
Price